Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Disaster in Medical-Device Land

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Take a recession where many people have lost their health-care insurance and add in pressure to lower health-care costs, and you have a recipe for disaster. Medtronic's (NYSE: MDT  ) first fiscal quarter revenue was up just 2% after adjusting for the longer quarter last year and currency fluctuations. Worse, the company dropped its revenue guidance from 5% to 8% growth down to just 2% to 5% growth year over year.

The poor prognosis from the medical-device maker caused a 10% drop in Medtronic's shares. Disaster might be an understatement.

Medtronic's fiscal quarters are one month delayed from the rest of the competition, so the results could foretell weaker sales by other medical-device makers Boston Scientific (NYSE: BSX  ) , Johnson & Johnson (NYSE: JNJ  ) , St. Jude Medical (NYSE: STJ  ) , and Stryker (NYSE: SYK  ) that it competes against directly. Even Intuitive Surgical (Nasdaq: ISRG  ) is down in sympathy, despite the fact that it doesn't compete directly. It's still tied to hospital spending, however.

The summer months are always a bit slow as doctors and patients take vacation, but the worry is that many patients are delaying surgeries that don't need to be performed right away. For long-term investors, the delay isn't a major issue since the demand will just be higher once the patients decide they can't wait any longer; hearts and spines don't usually fix themselves.

The bigger issue is that the push for lower health-care costs may be ending the era of continually rising prices. In order to increase revenue, companies will need to launch new devices that add value to the patient.

Medtronic's forecast is disappointing for the industry, but some of the issues are specific to Medtronic. Boston Scientific wasn't able to ship its defibrillators for about a month earlier this year, but Medtronic doesn't seem to have captured any of the market share; the medical-device maker has a 47% share of the implantable defibrillator market, the same share it had before Boston Scientific ran into issues.

Should investors in medical-device makers be worried? Absolutely, but then we should all be worried about the economy. Unfortunately, we'll all have to wait another couple of months when third-quarter results are released before we'll know how bad it is for the rest of the industry.

Stryker is a Motley Fool Inside Value recommendation. Intuitive Surgical is a Rule Breakers pick. Johnson & Johnson is a Motley Fool Income Investor recommendation and Motley Fool Options has recommended a diagonal call position on its shares. The Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (13)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 02, 2010, at 8:29 AM, rmiers wrote:

    I am amazed at the never ending attack at the Davinchi technology. Maybe they never should have called it robotic?

    Maybe the Intuitive surgical folks misjudged the dishonesty and selfishness of the medical community?

    It is known that the Davinchi owns the prostate surgical market, but look how long it took for the truth to come out. How many patients underwent discomfort, infection, and loss of productivity in the meantime? Even death?

    Now that hysterectomy treatment is coming down the pike, I guess the same folks are having an apoplexy that the truth of their recommendations in the past will become public. They only have one choice, continue to badmouth and call into question the use and outcomes of a great medical marvel and a gift to mankind.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1279384, ~/Articles/ArticleHandler.aspx, 10/26/2016 11:27:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,226.59 57.32 0.32%
S&P 500 2,144.51 1.35 0.06%
NASD 5,277.07 -6.33 -0.12%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 11:11 AM
BSX $22.47 Up +0.03 +0.11%
Boston Scientific CAPS Rating: ***
ISRG $673.29 Down -6.21 -0.91%
Intuitive Surgical CAPS Rating: ****
JNJ $115.10 Up +1.14 +1.00%
Johnson and Johnso… CAPS Rating: ****
MDT $81.20 Down -1.27 -1.54%
Medtronic CAPS Rating: *****
STJ $79.07 Up +0.06 +0.08%
St. Jude Medical CAPS Rating: **
SYK $110.60 Down -2.59 -2.29%
Stryker CAPS Rating: *****